The physician decides the orientation of the implant, and it is repositionable, allowing for any necessary corrections. The new Generation of the Device has an improved exterior to seal off the left atrial appendage better than the original model.
“The WATCHMAN Device has been implanted in more than 75,000 patients worldwide and we are pleased that this next-generation technology has been granted European regulatory approval so that we can offer it to patients and clinicians throughout*Europe,” said*Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. “The robust clinical evidence and successful commercial outcomes of the WATCHMAN Device to-date reinforce the value of this procedure for all appropriate patients.”
03-14-2019, 05:57 PM
Boston Sci’s Next Generation WATCHMAN FLX Stroke-Preventing Device Cleared in EU
Boston Scientific landed the European CE Mark for its Next Generation of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) device. The Device is used to isolate the left atrial appendage of the heart, the place where stroke-causing blood clots tend to form in patients with non-valvular atrial fibrillation (AFib).
العرض العادي
